Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium infantis R0033 + bifidobacterium bifidum R0071
- Development stage
- Unknown
- Lead developer
- Lallemand Health Solutions
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis R0033 + Bifidobacterium bifidum R0071 is a probiotic combination therapy consisting of two specific bacterial strains developed by Lallemand Health Solutions. This combination is primarily investigated for its therapeutic potential in managing lactose intolerance, particularly in pediatric populations. The mechanism of action involves the production of the enzyme $\beta$-galactosidase (lactase) by the probiotic strains, which facilitates the hydrolysis of lactose into glucose and galactose within the intestinal lumen, thereby compensating for endogenous lactase deficiency. Additionally, these strains contribute to the stabilization and modulation of the gut microbiota, enhancing intestinal barrier function and reducing the inflammatory response associated with malabsorption. Clinical research, including studies sponsored by the Chongqing Health Center for Women and Children, focuses on the efficacy of this blend in reducing gastrointestinal symptoms such as abdominal pain, bloating, and diarrhea in children with lactose malabsorption.
- Other names
- B. infantis R0033 + B. bifidum R0071Bifidobacterium infantis Rosell-33 + Bifidobacterium bifidum Rosell-71
Beyond the preview
Go deeper on bifidobacterium infantis R0033 + bifidobacterium bifidum R0071.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium infantis R0033 + bifidobacterium bifidum R0071.